Literature DB >> 2583687

Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease.

C Müller1, P Knoflach, C C Zielinski.   

Abstract

Serum levels of soluble interleukin 2 receptor were determined in patients with acute viral hepatitis and patients with various chronic liver diseases. In addition, the ability of peripheral blood mononuclear cells of patients with alcoholic cirrhosis to generate soluble interleukin 2 receptor following mitogenic stimulation was studied in vitro. Serum soluble interleukin 2 receptor concentrations in all patients with acute viral hepatitis were found to be significantly elevated (1,319 +/- 527 units per ml) during the first week after onset of disease, as compared to healthy control individuals (375 +/- 102 units per ml; p less than 0.0005) and declined toward normal levels during the course of the illness. Similarly, patients suffering from chronic liver disease such as alcoholic liver cirrhosis (1,172 +/- 507 units per ml), primary biliary cirrhosis (619 +/- 190 units per ml) or chronic active HBsAg+ hepatitis (941 +/- 357 units per ml) showed increased serum soluble interleukin 2 receptor concentrations (p less than 0.0005 vs. controls, respectively). In vitro mitogen stimulation of peripheral mononuclear cells derived from patients with alcoholic cirrhosis resulted in a soluble interleukin 2 receptor production not different from that seen in healthy individuals, suggesting that elevated soluble interleukin 2 receptor serum levels seen in this disease are not the result of an increased synthesis by circulating lymphocytes. Due to the ability of soluble interleukin 2 receptor to bind free interleukin 2--thus making it a potential immunoregulatory molecule--its high serum levels could explain some of the immunologic abnormalities observed in acute and chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583687     DOI: 10.1002/hep.1840100606

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Low serum levels of alpha-interferon, gamma-interferon, and interleukin-2 in alcoholic cirrhosis.

Authors:  M M Vicente-Gutiérrez; A Diez Ruiz; B Gil Extremera; J M Bermúdez García; F Gutiérrez Gea
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

2.  Increased expression of cytokines in liver and serum in patients with extrahepatic diseases.

Authors:  H Fukuma; S A Morshed; S Watanabe; N Uchida; T Ezaki; A Minami; H Matsuoka; S Hirabayashi; T Nakatsu; M Nishioka
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

3.  Serum soluble interleukin-2 receptor levels in patients with chronic hepatitis B virus infection and its relation with anti-HBc.

Authors:  Ping Xiao; Qing-Feng Chen; Yan-Ling Yang; Zhen-Hua Guo; Hong Chen
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

4.  Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection.

Authors:  Y Sawayama; J Hayashi; Y Kawakami; N Furusyo; I Ariyama; Y Kishihara; K Ueno; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

5.  Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitis.

Authors:  C Müller; P Knoflach; C C Zielinski
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

6.  Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha.

Authors:  J A Quiroga; J Martin; M Pardo; V Carreño
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

7.  Acquired Hemophagocytic Lymphohistiocytosis Associated With Disseminated Herpes Simplex Virus in Immunocompetent Host.

Authors:  Michael Schwartz; Courtney O'Brien; Nischal Raya; Nancy Reau
Journal:  ACG Case Rep J       Date:  2019-08-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.